Crossmark

Rapid hippocampal synaptic potentiation induced by ketamine metabolite (2R,6R)-hydroxynorketamine persistently primes synaptic plasticity

Published Online: 2025-03-17

Published Print: 2025-05

Authors

Brown, Kyle A.

Ajibola, Musa I.

Gould, Todd D. https://orcid.org/0000-0003-1511-7183
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | National Institutes of Health (MH107615)

U.S. Department of Veterans Affairs (1I01BX004062, 101BX003631)
License Information

Text and Data Mining valid from 2025-03-17

Version of Record valid from 2025-03-17
More Information

Article History

Received: 24 October 2024

Revised: 20 February 2025

Accepted: 3 March 2025

First Online: 17 March 2025

Competing interests

: TDG is listed as co-author in patents and patent applications related to the pharmacology and use of (2R,6R)-HNK in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. TDG has assigned his patent rights to the University of Maryland, Baltimore, but will share a percentage of any royalties that may be received by the University of Maryland, Baltimore. The contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. TDG has served as a consultant for Boehringer Ingelheim during the preceding 3 years. All other authors report no conflict of interest.

Document is current